128 related articles for article (PubMed ID: 15341609)
1. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates.
Decamp E; Schneider JS
Eur J Neurosci; 2004 Sep; 20(5):1371-8. PubMed ID: 15341609
[TBL] [Abstract][Full Text] [Related]
2. Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys.
Decamp E; Schneider JS
Eur J Neurosci; 2006 Oct; 24(7):2098-104. PubMed ID: 17067307
[TBL] [Abstract][Full Text] [Related]
3. Attentional cueing reverses deficits in spatial working memory task performance in chronic low dose MPTP-treated monkeys.
Decamp E; Tinker JP; Schneider JS
Behav Brain Res; 2004 Jul; 152(2):259-62. PubMed ID: 15196793
[TBL] [Abstract][Full Text] [Related]
4. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys.
Schneider JS; Tinker JP; Van Velson M; Menzaghi F; Lloyd GK
J Pharmacol Exp Ther; 1999 Aug; 290(2):731-9. PubMed ID: 10411585
[TBL] [Abstract][Full Text] [Related]
5. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats.
Rodefer JS; Murphy ER; Baxter MG
Eur J Neurosci; 2005 Feb; 21(4):1070-6. PubMed ID: 15787711
[TBL] [Abstract][Full Text] [Related]
6. Long-term cognitive impairment in MPTP-treated rhesus monkeys.
Fernandez-Ruiz J; Doudet DJ; Aigner TG
Neuroreport; 1995 Dec; 7(1):102-4. PubMed ID: 8742427
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD.
Rane P; Shields J; Heffernan M; Guo Y; Akbarian S; King JA
Neuropharmacology; 2012 Jun; 62(7):2409-12. PubMed ID: 22353286
[TBL] [Abstract][Full Text] [Related]
8. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
9. Task persistence and learning ability in normal and chronic low dose MPTP-treated monkeys.
Roeltgen DP; Schneider JS
Behav Brain Res; 1994 Feb; 60(2):115-24. PubMed ID: 8003241
[TBL] [Abstract][Full Text] [Related]
10. Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.
Goldstein DS; Li ST; Holmes C; Bankiewicz K
J Pharmacol Exp Ther; 2003 Sep; 306(3):855-60. PubMed ID: 12805479
[TBL] [Abstract][Full Text] [Related]
11. The impact of Parkinson's disease on sequence learning: perceptual pattern learning and executive function.
Price A; Shin JC
Brain Cogn; 2009 Mar; 69(2):252-61. PubMed ID: 18786754
[TBL] [Abstract][Full Text] [Related]
12. D-Amphetamine remediates attentional performance in rats with dorsal prefrontal lesions.
Chudasama Y; Nathwani F; Robbins TW
Behav Brain Res; 2005 Mar; 158(1):97-107. PubMed ID: 15680198
[TBL] [Abstract][Full Text] [Related]
13. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN
Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.
Lewis SJ; Slabosz A; Robbins TW; Barker RA; Owen AM
Neuropsychologia; 2005; 43(6):823-32. PubMed ID: 15716155
[TBL] [Abstract][Full Text] [Related]
15. Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model.
Schneider JS; Pioli EY; Jianzhong Y; Li Q; Bezard E
Mov Disord; 2013 May; 28(5):663-7. PubMed ID: 23238827
[TBL] [Abstract][Full Text] [Related]
16. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Schneider JS; Tinker JP; Menzaghi F; Lloyd GK
J Pharmacol Exp Ther; 2003 Jul; 306(1):401-6. PubMed ID: 12721323
[TBL] [Abstract][Full Text] [Related]
17. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.
Jakowec MW; Petzinger GM
Comp Med; 2004 Oct; 54(5):497-513. PubMed ID: 15575363
[TBL] [Abstract][Full Text] [Related]
18. Chronic low-dose MPTP in nonhuman primates: a possible model for attention deficit disorder.
Roeltgen DP; Schneider JS
J Child Neurol; 1991; 6 Suppl():S82-9. PubMed ID: 2002219
[TBL] [Abstract][Full Text] [Related]
19. A highly sensitive automated complex running wheel test to detect latent motor deficits in the mouse MPTP model of Parkinson's disease.
Liebetanz D; Baier PC; Paulus W; Meuer K; Bähr M; Weishaupt JH
Exp Neurol; 2007 May; 205(1):207-13. PubMed ID: 17341420
[TBL] [Abstract][Full Text] [Related]
20. Attention and executive functions in remitted major depression patients.
Paelecke-Habermann Y; Pohl J; Leplow B
J Affect Disord; 2005 Dec; 89(1-3):125-35. PubMed ID: 16324752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
